Emyria (ASX:EMD) Total Stockholders Equity: A$12.10 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emyria Total Stockholders Equity?

Emyria ASX:EMD Total Stockholders Equity is A$12.10 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Emyria's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$12.10 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Emyria's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Emyria's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.05.

Emyria  (ASX:EMD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Emyria's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(12.101-0)/804.251
=0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Emyria's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.055 + 0.502) / 12.101
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Total Stockholders Equity Related Terms

Emyria Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Emyria's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Total Stockholders Equity Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial 7.18 6.32 6.79 2.43 5.31

Emyria Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 2.43 3.41 5.31 12.10
What does a Total Stockholders Equity of A$12.10 Mil mean?
Emyria (ASX:EMD) has a Total Stockholders Equity of A$12.10 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Emyria and its competitors.
Is Emyria's Total Stockholders Equity too high?
Emyria's current Total Stockholders Equity is A$12.10 Mil.
How does Emyria's Total Stockholders Equity compare to VEEV and BTSG?
Emyria's Total Stockholders Equity of A$12.10 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Healthcare Providers & Services company?
A good Total Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Emyria and its competitors. Emyria's current Total Stockholders Equity is A$12.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.05 — trading 56.7% above its estimated fair value. The current Total Stockholders Equity is A$12.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Total Stockholders Equity is A$12.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emyria Business Description

Other Exchanges Q84:Germany
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.